AAV Packaging Service in Large Scale
Features:
- Nonpathogenic with least immune response and best suitable for in
vivo application.
- Excellent gene delivery efficiency
in most cell types including dividing and non-dividing or primary cells.
- Persistent transgene expression.
- Multiple serotypes (AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-DJ/8 and AAV-DJ).
Service
Description:
- rAAV packaging
in 2xcell stack.
- rAAV purification via advanced 2xCsCl ultra-centrifugation.
- Desalting, filter sterilization and AAV titration via qPCR.
rAAV Serotypes We Offer:
AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-PHP.B, AAV-PHP.eB,
AAV-PHP.S, AAV-DJ/8
and AAV-DJ.
Required Materials:
AAV cis plasmid carrying your gene of interest (GOI), >300 µg.
Turnaround Time:
1
~ 2 weeks.
Deliverables: >1.0 mL of super purified in vivo grade rAAV
vector at >1E+13 VG/mL*.
We offer discount for new customer, please
request a quote with us
today.
Service Inquiry / Request a Quote
Super High Yield:
With our proprietary genetically engineered AAV·HT™ packaging cell and
a modified rAAV cis vector, the rAAV yield is easy to reach super high
level--------total 1E+15 VG. For super high level rAAV production up to
1E+15 VG total, please
contact us to request a quote.
Figure 1. A comparison of purity and infectivity of rAAV vectors from
different sources showing super purified and super infectious (close to
clinical trial grade) rAAV vector prepared via our advanced double CsCl
ultra-centrifugation approach.
A. rAAV
vectors (total 1E+9 VG per lane) from different sources were
resolved on SDS-PAGE followed by silver staining. Lane 1: GMP
manufactured rAAV vector from CHOP; Lane 2: rAAV prepared via our
advanced 2xCsCl ultra-centrifugation approach; Lane 3: rAAV from Vector
Core of BCM; Lane 4: rAAV from our competitor "V"; Lane 5: rAAV from
our competitor "C"; Lane 6: Protein marker.
B. Super infectious rAAV vector prepared via advanced
double CsCl ultra-centrifugation.
Left panel: rAAV2-CAG-GFP (total 5E+9 VG) from our competitor "V" injected
to mouse eye; Right panel:
rAAV2-CAG-GFP (total 5E+9 VG) purified via
advanced 2xCsCl ultra-centrifugation injected
to mouse eye.
Figure 2. A comparison of infectivity of rAAV vectors from different
sources showing super purified rAAV prepared via advanced double CsCl
ultra-centrifugation approach is super infectious.
rAAV1-GFP
(total 2E+9 VG) from different sources were injected to mouse muscle
tissue. The GFP fluorescence was visualized 3 weeks post
injection. A. rAAV1-GFP from our competitor "V"; B. rAAV1-GFP
from our pre-made rAAVs stock purified via advanced
double CsCl ultra-centrifugation. C.
Quantification data showed that our super purified rAAV (bar 2) is ~ 9
times more infectious than that (bar 1) prepared via conventional CsCl
ultra-centrifugation.
* Final viral yield may depend on the
nature of transgene.
